34 results on '"Allen, Matthew R."'
Search Results
2. Inhibition of RANKL improves the skeletal phenotype of adenine-induced chronic kidney disease in mice.
- Author
-
Metzger, Corinne E, Kittaka, Mizuho, LaPlant, Alec N, Ueki, Yasuyoshi, and Allen, Matthew R
- Subjects
BONE resorption ,CHRONIC kidney failure ,TRANCE protein ,COMPACT bone ,BONE mechanics ,BLOOD urea nitrogen ,BONE remodeling - Abstract
Skeletal fragility and high fracture rates are common in CKD. A key component of bone loss in CKD with secondary hyperparathyroidism is high bone turnover and cortical bone deterioration through both cortical porosity and cortical thinning. We hypothesized that RANKL drives high bone resorption within cortical bone leading to the development of cortical porosity in CKD (study 1) and that systemic inhibition of RANKL would mitigate the skeletal phenotype of CKD (study 2). In study 1, we assessed the skeletal properties of male and female Dmp1-cre RANKL
fl/fl (cKO) and control genotype (Ranklfl/fl ; Con) mice after 10 wk of adenine-induced CKD (AD; 0.2% dietary adenine). All AD mice regardless of sex or genotype had elevated blood urea nitrogen and high PTH. Con AD mice in both sexes had cortical porosity and lower cortical thickness as well as high osteoclast-covered trabecular surfaces and higher bone formation rate. cKO mice had preserved cortical bone microarchitecture despite high circulating PTH as well as no CKD-induced increases in osteoclasts. In study 2, male mice with established AD CKD were either given a single injection of an anti-RANKL antibody (5 mg/kg) 8 wk post-induction of CKD or subjected to 3×/wk dosing with risedronate (1.2 μg/kg) for 4 wk. Anti-RANKL treatment significantly reduced bone formation rate as well as osteoclast surfaces at both trabecular and cortical pore surfaces; risedronate treatment had little effect on these bone parameters. In conclusion, these studies demonstrate that bone-specific RANKL is critical for the development of high bone formation/high osteoclasts and cortical bone loss in CKD with high PTH. Additionally, systemic anti-RANKL ligand therapy in established CKD may help prevent the propagation of cortical bone loss via suppression of bone turnover. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
3. What Animal Models Have Taught Us About the Safety and Efficacy of Bisphosphonates in Chronic Kidney Disease
- Author
-
Allen, Matthew R. and Aref, Mohammad W.
- Published
- 2017
- Full Text
- View/download PDF
4. Effects of ferric citrate and intravenous iron sucrose on markers of mineral, bone, and iron homeostasis in a rat model of CKD-MBD.
- Author
-
Biruete, Annabel, Metzger, Corinne E, Chen, Neal X, Swallow, Elizabeth A, Vrabec, Curtis, Clinkenbeard, Erica L, Stacy, Alexander J, Srinivasan, Shruthi, O'Neill, Kalisha, Avin, Keith G, Allen, Matthew R, and Moe, Sharon M
- Subjects
RENAL osteodystrophy ,IRON ,BONE mechanics ,ANIMAL disease models ,SUCROSE ,COMPACT bone - Abstract
Background Anemia and chronic kidney disease–mineral and bone disorder (CKD-MBD) are common and begin early in CKD. Limited studies have concurrently compared the effects of ferric citrate (FC) versus intravenous (IV) iron on CKD-MBD and iron homeostasis in moderate CKD. Methods We tested the effects of 10 weeks of 2% FC versus IV iron sucrose in rats with moderate CKD (Cy/+ male rat) and untreated normal (NL) littermates. Outcomes included a comprehensive assessment of CKD-MBD, iron homeostasis and oxidative stress. Results CKD rats had azotemia, elevated phosphorus, parathyroid hormone and fibroblast growth factor-23 (FGF23). Compared with untreated CKD rats, treatment with FC led to lower plasma phosphorus, intact FGF23 and a trend (P = 0.07) toward lower C-terminal FGF23. FC and IV iron equally reduced aorta and heart calcifications to levels similar to NL animals. Compared with NL animals, CKD animals had higher bone turnover, lower trabecular volume and no difference in mineralization; these were unaffected by either iron treatment. Rats treated with IV iron had cortical and bone mechanical properties similar to NL animals. FC increased the transferrin saturation rate compared with untreated CKD and NL rats. Neither iron treatment increased oxidative stress above that of untreated CKD. Conclusions Oral FC improved phosphorus homeostasis, some iron-related parameters and the production and cleavage of FGF23. The intermittent effect of low-dose IV iron sucrose on cardiovascular calcification and bone should be further explored in moderate–advanced CKD. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
5. Forward: A Fresh Look at Measuring and Altering Bone Quality
- Author
-
Allen, Matthew R.
- Published
- 2016
- Full Text
- View/download PDF
6. Blueberry Polyphenols do not Improve Bone Mineral Density or Mechanical Properties in Ovariectomized Rats.
- Author
-
Cladis, Dennis P., Swallow, Elizabeth A., Allen, Matthew R., Hill Gallant, Kathleen M., and Weaver, Connie M.
- Subjects
BONE mechanics ,POLYPHENOLS ,BLUEBERRIES ,SPRAGUE Dawley rats ,PUBLIC health - Abstract
Osteoporosis-related bone fragility fractures are a major public health concern. Given the potential for adverse side effects of pharmacological treatment, many have sought alternative treatments, including dietary changes. Based on recent evidence that polyphenol-rich foods, like blueberries, increase calcium absorption and bone mineral density (BMD), we hypothesized that blueberry polyphenols would improve bone biomechanical properties. To test this, 5-month-old ovariectomized Sprague-Dawley rats (n = 10/gp) were orally gavaged for 90 days with either a purified extract of blueberry polyphenols (0–1000 mg total polyphenols/kg bw/day) or lyophilized blueberries (50 mg total polyphenols/kg bw/day). Upon completion of the dosing regimen, right femur, right tibia, and L1–L4 vertebrae were harvested and assessed for bone mineral density (BMD), with femurs being further analyzed for biomechanical properties via three-point bending. There were no differences in BMD at any of the sites analyzed. For bone mechanical properties, the only statistically significant difference was the high dose group having greater ultimate stress than the medium dose, although in the absence of differences in other measures of bone mechanical properties, we concluded that this result, while statistically significant, had little biological significance. Our results indicate that blueberry polyphenols had little impact on BMD or bone mechanical properties in an animal model of estrogen deficiency-induced bone loss. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
7. Carbon Monoxide and Exercise Prevents Diet‐Induced Obesity and Metabolic Dysregulation Without Affecting Bone.
- Author
-
Gasier, Heath G., Yu, Tianzheng, Swift, Joshua M., Metzger, Corrine E., McNerny, Erin M., Swallow, Elizabeth A., Piantadosi, Claude A., and Allen, Matthew R.
- Subjects
BONES ,CARBON monoxide ,BONE mechanics ,WEIGHT loss ,OBESITY - Abstract
Objective: Carbon monoxide (CO) may counteract obesity and metabolic dysfunction in rodents consuming high‐fat diets, but the skeletal effects are not understood. This study investigated whether low‐dose inhaled CO (250 ppm) with or without moderate intensity aerobic exercise (3 h/wk) would limit diet‐induced obesity and metabolic dysregulation and preserve bone health. Methods: Obesity‐resistant (OR) rats served as controls, and obesity‐prone (OP) rats were randomized to sedentary, sedentary plus CO, exercise, or CO plus exercise. For 10 weeks, OP rats consumed a high‐fat, high‐sucrose diet, whereas OR rats consumed a low‐fat control diet. Measurements included indicators of obesity and metabolism, bone turnover markers, femoral geometry and microarchitecture, bone mechanical properties, and tibial morphometry. Results: A high‐fat, high‐sucrose diet led to obesity, hyperinsulinemia, and hyperleptinemia, without impacting bone. CO alone led only to a modest reduction in weight gain. Exercise attenuated weight gain and improved the metabolic profile; however, bone fragility increased. Combined CO and exercise led to body mass reduction and a metabolic state similar to control OR rats and prevented the exercise‐induced increase in bone fragility. Conclusions: CO and aerobic exercise training prevent obesity and metabolic sequelae of nutrient excess while stabilizing bone physiology. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. N-acetylcysteine (NAC), an anti-oxidant, does not improve bone mechanical properties in a rat model of progressive chronic kidney disease-mineral bone disorder.
- Author
-
Allen, Matthew R., Wallace, Joseph, McNerney, Erin, Nyman, Jeffry, Avin, Keith, Chen, Neal, and Moe, Sharon
- Subjects
- *
BONE mechanics , *BONES , *ADVANCED glycation end-products , *TERIPARATIDE , *CHRONIC kidney failure - Abstract
Individuals with chronic kidney disease have elevated levels of oxidative stress and are at a significantly higher risk of skeletal fracture. Advanced glycation end products (AGEs), which accumulate in bone and compromise mechanical properties, are known to be driven in part by oxidative stress. The goal of this study was to study effects of N-acetylcysteine (NAC) on reducing oxidative stress and improving various bone parameters, most specifically mechanical properties, in an animal model of progressive CKD. Male Cy/+ (CKD) rats and unaffected littermates were untreated (controls) or treated with NAC (80 mg/kg, IP) from 30 to 35 weeks of age. Endpoint measures included serum biochemistries, assessments of systemic oxidative stress, bone morphology, and mechanical properties, and AGE levels in the bone. CKD rats had the expected phenotype that included low kidney function, elevated parathyroid hormone, higher cortical porosity, and compromised mechanical properties. NAC treatment had mixed effects on oxidative stress markers, significantly reducing TBARS (a measure of lipid peroxidation) while not affecting 8-OHdG (a marker of DNA oxidation) levels. AGE levels in the bone were elevated in CKD animals and were reduced with NAC although this did not translate to a benefit in bone mechanical properties. In conclusion, NAC failed to significantly improve bone architecture/geometry/mechanical properties in our rat model of progressive CKD. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
9. Osteocytic miR21 deficiency improves bone strength independent of sex despite having sex divergent effects on osteocyte viability and bone turnover.
- Author
-
Davis, Hannah M., Deosthale, Padmini J., Pacheco‐Costa, Rafael, Essex, Alyson L., Atkinson, Emily G., Aref, Mohammad W., Dilley, Julian E., Bellido, Teresita, Ivan, Mircea, Allen, Matthew R., and Plotkin, Lilian I.
- Subjects
BONE resorption ,BONES ,OSTEOBLASTS ,BONE mechanics ,BONE metabolism ,HUMAN sexuality ,OSTEOCYTES - Abstract
Osteocytes play a critical role in mediating cell–cell communication and regulating bone homeostasis, and osteocyte apoptosis is associated with increased bone resorption. miR21, an oncogenic microRNA, regulates bone metabolism by acting directly on osteoblasts and osteoclasts, but its role in osteocytes is not clear. Here, we show that osteocytic miR21 deletion has sex‐divergent effects in bone. In females, miR21 deletion reduces osteocyte viability, but suppresses bone turnover. Conversely, in males, miR21 deletion increases osteocyte viability, but stimulates bone turnover and enhances bone structure. Further, miR21 deletion differentially alters osteocyte cytokine production in the two sexes. Interestingly, despite these changes, miR21 deletion increases bone mechanical properties in both sexes, albeit to a greater extent in males. Collectively, our findings suggest that miR21 exerts both sex‐divergent and sex‐equivalent roles in osteocytes, regulating osteocyte viability and altering bone metabolism through paracrine actions on osteoblasts and osteoclasts differentially in males vs females, whereas, influencing bone mechanical properties independent of sex. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
10. Loss of Nmp4 optimizes osteogenic metabolism and secretion to enhance bone quality.
- Author
-
Yu Shao, Wichern, Emily, Childress, Paul J., Adaway, Michele, Misra, Jagannath, Klunk, Angela, Burr, David B., Wek, Ronald C., Mosley, Amber L., Yunlong Liu, Robling, Alexander G., Brustovetsky, Nickolay, Hamilton, James, Jacobs, Kylie, Vashishth, Deepak, Stayrook, Keith R., Allen, Matthew R., Wallace, Joseph M., and Bidwell, Joseph P.
- Subjects
BONE growth ,NUCLEAR matrix ,BONE mechanics ,SECRETION ,CELL analysis ,METABOLISM - Abstract
A goal of osteoporosis therapy is to restore lost bone with structurally sound tissue. Mice lacking the transcription factor nuclear matrix protein 4 (Nmp4, Zfp384, Ciz, ZNF384) respond to several classes of osteoporosis drugs with enhanced bone formation compared with wild-type (WT) animals. Nmp4
-/- mesenchymal stem/progenitor cells (MSPCs) exhibit an accelerated and enhanced mineralization during osteoblast differentiation. To address the mechanisms underlying this hyperanabolic phenotype, we carried out RNA-sequencing and molecular and cellular analyses of WT and Nmp4-/- MSPCs during osteogenesis to define pathways and mechanisms associated with elevated matrix production. We determined that Nmp4 has a broad impact on the transcriptome during osteogenic differentiation, contributing to the expression of over 5,000 genes. Phenotypic anchoring of transcriptional data was performed for the hypothesis-testing arm through analysis of cell metabolism, protein synthesis and secretion, and bone material properties. Mechanistic studies confirmed that Nmp4-/- MSPCs exhibited an enhanced capacity for glycolytic conversion: a key step in bone anabolism. Nmp4-/- cells showed elevated collagen translation and secretion. The expression of matrix genes that contribute to bone material-level mechanical properties was elevated in Nmp4-/- cells, an observation that was supported by biomechanical testing of bone samples from Nmp4-/- and WT mice. We conclude that loss of Nmp4 increases the magnitude of glycolysis upon the metabolic switch, which fuels the conversion of the osteoblast into a super-secretor of matrix resulting in more bone with improvements in intrinsic quality. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
11. Raloxifene Improves Bone Mechanical Properties in Mice Previously Treated with Zoledronate.
- Author
-
Meixner, Cory, Aref, Mohammad, Gupta, Aryaman, McNerny, Erin, Brown, Drew, Wallace, Joseph, Allen, Matthew, Meixner, Cory N, Aref, Mohammad W, McNerny, Erin M B, Wallace, Joseph M, and Allen, Matthew R
- Subjects
BONE mechanics ,RALOXIFENE ,ZOLEDRONIC acid ,DIPHOSPHONATES ,LABORATORY mice ,THERAPEUTICS ,BONE remodeling ,ANIMAL experimentation ,BONES ,FEMUR ,IMIDAZOLES ,KINEMATICS ,MICE ,RESEARCH funding ,BONE density ,PHARMACODYNAMICS - Abstract
Bisphosphonates represent the gold-standard pharmaceutical agent for reducing fracture risk. Long-term treatment with bisphosphonates can result in tissue brittleness which in rare clinical cases manifests as atypical femoral fracture. Although this has led to an increasing call for bisphosphonate cessation, few studies have investigated therapeutic options for follow-up treatment. The goal of this study was to test the hypothesis that treatment with raloxifene, a drug that has cell-independent effects on bone mechanical material properties, could reverse the compromised mechanical properties that occur following zoledronate treatment. Skeletally mature male C57Bl/6J mice were treated with vehicle (VEH), zoledronate (ZOL), or ZOL followed by raloxifene (RAL; 2 different doses). At the conclusion of 8 weeks of treatment, femora were collected and assessed with microCT and mechanical testing. Trabecular BV/TV was significantly higher in all treated animals compared to VEH with both RAL groups having significantly higher BV/TV compared to ZOL (+21%). All three drug-treated groups had significantly more cortical bone area, higher cortical thickness, and greater moment of inertia at the femoral mid-diaphysis compared to VEH with no difference among the three treated groups. All three drug-treated groups had significantly higher ultimate load compared to VEH-treated animals (+14 to 18%). Both doses of RAL resulted in significantly higher displacement values compared to ZOL-treated animals (+25 to +50%). In conclusion, the current work shows beneficial effects of raloxifene in animals previously treated with zoledronate. The higher mechanical properties of raloxifene-treated animals, combined with similar cortical bone geometry compared to animals treated with zoledronate, suggest that the raloxifene treatment is enhancing mechanical material properties of the tissue. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
12. Variability of in vivo reference point indentation in skeletally mature inbred rats.
- Author
-
Allen, Matthew R., Newman, Christopher L., Smith, Eric, Brown, Drew M., and Organ, Jason M.
- Subjects
- *
TREATMENT of fractures , *INDENTATION (Materials science) , *BIOMECHANICS , *LABORATORY rats , *HEALTH outcome assessment , *ANIMAL models in research - Abstract
Reference point indentation (RPI) has emerged as a novel tool to measure material-level biomechanical properties in vivo. Human studies have been able to differentiate fracture versus non-fracture patients while a dog study has shown the technique can differentiate drug treatment effects. The goal of this study was to extend this technology to the in vivo measurement of rats, one of the most common animal models used to study bone, with assessment of intra- and inter-animal variability. Seventy-two skeletally mature male Sprague-Dawley rats were subjected to in vivo RPI on the region between the tibial diaphysis and proximal metaphysis. RPI data were assessed using a custom MATLAB program to determine several outcome parameters, including first cycle indentation distance (ID-1st), indentation distance increase (IDI), total indentation distance (TID), first cycle unloading slope (US-1st), and first cycle energy dissipation (ED-1st). Intra-animal variability ranged from 13% to 21% with US-1st and Tot Ed 1st-L being the least variable properties and IDI the most highly variable. Inter-animal variability ranged from 16% (US-1st) to 25% (ED-1st and IDI). Based on these data, group size estimates would need to range from 9 to 18/group to achieve sufficient power for detecting a 25% difference in a two-group experiment. Repeat tests on the contralateral limb of a small cohort of animals (n = 17) showed non-significant differences over 28 days ranging from - 6% to -18%. These results provide important data on RPI variability (intra- and inter-animal) in rats that can be used to properly power future experiments using this technique. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
13. Cortical Bone Mechanical Properties Are Altered in an Animal Model of Progressive Chronic Kidney Disease.
- Author
-
Newman, Christopher L., Moe, Sharon M., Chen, Neal X., Hammond, Max A., Wallace, Joseph M., Nyman, Jeffry S., and Allen, Matthew R.
- Subjects
KIDNEY diseases ,DISEASE progression ,BONE mechanics ,ATOMIC force microscopy ,ENERGY dissipation ,HIGH performance liquid chromatography ,RAMAN spectroscopy - Abstract
Chronic kidney disease (CKD), which leads tocortical bone loss and increasedporosity,increases therisk of fracture. Animal models have confirmed that these changes compromise whole bone mechanical properties. Estimates from whole bone testing suggest that material properties are negatively affected, though tissue-level assessmentshavenot been conducted. Therefore, the goal of the present study was to examine changes in cortical bone at different length scales using a rat model with theprogressive development of CKD. At 30 weeks of age (∼75% reduction in kidney function), skeletally mature male Cy/+ rats were compared to their normal littermates. Cortical bone material propertieswere assessed with reference point indentation (RPI), atomic force microscopy (AFM), Raman spectroscopy,and high performance liquid chromatography (HPLC). Bones from animals with CKD had higher (+18%) indentation distance increase and first cycle energy dissipation (+8%) as measured by RPI.AFM indentation revealed a broader distribution of elastic modulus values in CKD animals witha greater proportion of both higher and lower modulus values compared to normal controls. Yet, tissue composition, collagen morphology, and collagen cross-linking fail to account for these differences. Though the specific skeletal tissue alterations responsible for these mechanical differences remain unclear, these results indicate that cortical bone material properties are altered in these animals and may contribute to the increased fracture risk associated with CKD. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
14. Bisphosphonate effects on bone turnover, microdamage, and mechanical properties: What we think we know and what we know that we don't know
- Author
-
Allen, Matthew R. and Burr, David B.
- Subjects
- *
BONE mechanics , *BONE remodeling , *DIPHOSPHONATES , *BONE density , *SKELETON , *BONE fracture prevention , *ABSORPTION (Physiology) , *TISSUES - Abstract
Abstract: The bisphosphonates (BPs) have been useful tools in our understanding of the role that bone remodeling plays in skeletal health. The purpose of this paper is to outline what we know, and what is still unknown, about the role that BPs play in modulating bone turnover, how this affects microdamage accumulation, and ultimately what the effects of these changes elicited by BPs are to the structural and the material biomechanical properties of the skeleton. We know that BPs suppress remodeling site-specifically, probably do not have a direct effect on formation, and that the individual BPs vary with respect to speed of onset, duration of effect and magnitude of suppression. However, we do not know if these differences are meaningful in a clinical sense, how much remodeling is sufficient, the optimal duration of treatment, or how long it takes to restore remodeling to pre-treatment levels following withdrawal. We also know that suppression is intimately tied to microdamage accumulation, which is also site-specific, that BPs impair targeted repair of damage, and that they can reduce the energy absorption capacity of bone at the tissue level. However, the BPs are clearly effective at preventing fracture, and generally increase bone mineral density and whole bone strength, so we do not know whether these changes in damage accumulation and repair, or the mechanical effects at the tissue level, are clinically meaningful. The mechanical effects of BPs on the fatigue life of bone, or BP effects on bone subject to an impact, are entirely unknown. This paper reviews the literature on these topics, and identifies gaps in knowledge that can be addressed with further research. This article is part of a Special Issue entitled Bisphosphonates. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
15. Can deterministic mechanical size effects contribute to fracture and microdamage accumulation in trabecular bone?
- Author
-
Siegmund, Thomas, Allen, Matthew R., and Burr, David B.
- Subjects
- *
BONE mechanics , *BONE fractures , *CYCLIC loads , *BONE density , *BIOMECHANICS , *OSTEOPOROSIS - Abstract
Abstract: Failure of bone under monotonic and cyclic loading is related to the bone mineral density, the quality of the bone matrix, and the evolution of microcracks. The theory of linear elastic fracture mechanics has commonly been applied to describe fracture in bone. Evidence is presented that bone failure can be described through a non-linear theory of fracture. Thereby, deterministic size effects are introduced. Concepts of a non-linear theory are applied to discern how the interaction among bone matrix constituents (collagen and mineral), microcrack characteristics, and trabecular architecture can create distinctively differences in the fracture resistance at the bone tissue level. The non-linear model is applied to interpret pre-clinical data concerning the effects of anti-osteoporotic agents on bone properties. The results show that bisphosphonate (BP) treatments that suppress bone remodeling will change trabecular bone in ways such that the size of the failure process zone relative to the trabecular thickness is reduced. Selective estrogen receptor modulators (SERMs) that suppress bone remodeling will change trabecular bone in ways such that the size of the failure process zone relative to the trabecular thickness is increased. The consequences of these changes are reflected in bone mechanical response and predictions are consistent with experimental observations in the animal model which show that BP treatment is associated with more brittle fracture and microcracks without altering the average length of the cracks, whereas SERM treatments lead to a more ductile fracture and mainly increase crack length with a smaller increase in microcrack density. The model suggests that BPs may be more effective in cases in which bone mass is very low, whereas SERMS may be more effective when milder osteoporotic symptoms are present. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
16. Identification of material parameters based on Mohr–Coulomb failure criterion for bisphosphonate treated canine vertebral cancellous bone
- Author
-
Wang, Xiang, Allen, Matthew R., Burr, David B., Lavernia, Enrique J., Jeremić, Boris, and Fyhrie, David P.
- Subjects
- *
BONE mechanics , *DIPHOSPHONATES , *FINITE element method , *OSTEOPOROSIS - Abstract
Abstract: Nanoindentation has been widely used to study bone tissue mechanical properties. The common method and equations for analyzing nanoindentation, developed by Oliver and Pharr, are based on the assumption that the material is linearly elastic. In the present study, we adjusted the constraint of linearly elastic behavior and use nonlinear finite element analysis to determine the change in cancellous bone material properties caused by bisphosphonate treatment, based on an isotropic form of the Mohr–Coulomb failure model. Thirty-three canine lumbar vertebrae were used in this study. The dogs were treated daily for 1 year with oral doses of alendronate, risedronate, or saline vehicle at doses consistent, on a mg/kg basis, to those used clinically for the treatment of post-menopausal osteoporosis. Two sets of elastic modulus and hardness values were calculated for each specimen using the Continuous Stiffness Measurement (CSM) method (E CSM and H CSM) from the loading segment and the Oliver–Pharr method (E O–P and H O–P) from the unloading segment, respectively. Young''s modulus (E FE), cohesion (c), and friction angle (ϕ) were identified using a finite element model for each nanoindentation. The bone material properties were compared among groups and between methods for property identification. Bisphosphonate treatment had a significant effect on several of the material parameters. In particular, Oliver–Pharr hardness was larger for both the risedronate- and alendronate-treated groups compared to vehicle and the Mohr–Coulomb cohesion was larger for the risedronate-treated compared to vehicle. This result suggests that bisphosphonate treatment increases the hardness and shear strength of bone tissue. Shear strength was linearly predicted by modulus and hardness measured by the Oliver–Pharr method (r 2 =0.99). These results show that bisphosphonate-induced changes in Mohr–Coulomb material properties, including tissue shear cohesive strength, can be accurately calculated from Oliver–Pharr measurements of Young''s modulus and hardness. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
17. Human femoral neck has less cellular periosteum, and more mineralized periosteum, than femoral diaphyseal bone
- Author
-
Allen, Matthew R. and Burr, David B.
- Subjects
- *
BONE cells , *PERIOSTEUM , *FEMUR neck , *BONE mechanics - Abstract
Abstract: Periosteal expansion enhances bone strength and is controlled by osteogenic cells of the periosteum. The extent of cellular periosteum at the human femoral neck, a clinically relevant site, is unclear. This study was designed to histologically evaluate the human femoral neck periosteal surface. Femoral neck samples from 11 male and female cadavers (ages 34–88) were histologically assessed and four periosteal surface classifications (cellular periosteum, mineralizing periosteum, cartilage, and mineralizing cartilage) were quantified. Femoral mid-diaphysis samples from the same cadavers were used as within-specimen controls. The femoral neck surface had significantly less (P < 0.05) cellular periosteum (18.4 ± 9.7%) compared to the femoral diaphysis (59.2 ± 13.8%). A significant amount of the femoral neck surface was covered by mineralizing periosteal tissue (20–70%). These data may provide an alternate explanation for the apparent femoral neck periosteal expansion with age and suggest the efficiency of interventions that stimulate periosteal expansion may be reduced, albeit still possible, at the femoral neck of humans. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
18. Mechanics of linear microcracking in trabecular bone.
- Author
-
Hammond, Max A., Wallace, Joseph M., Allen, Matthew R., and Siegmund, Thomas
- Subjects
- *
MICROCRACKS , *CANCELLOUS bone , *BONE mechanics , *MECHANICAL stress analysis , *FINITE element method - Abstract
Abstract Microcracking in trabecular bone is responsible both for the mechanical degradation and remodeling of the trabecular bone tissue. Recent results on trabecular bone mechanics have demonstrated that bone tissue microarchitecture, tissue elastic heterogeneity and tissue-level mechanical anisotropy all should be considered to obtain detailed information on the mechanical stress state. The present study investigated the influence of tissue microarchitecture, tissue heterogeneity in elasticity and material separation properties and tissue-level anisotropy on the microcrack formation process. Microscale bone models were executed with the extended finite element method. It was demonstrated that anisotropy and heterogeneity of the bone tissue contribute significantly to bone tissue toughness and the resistance of trabecular bone to microcrack formation. The compressive strain to microcrack initiation was computed to increase by a factor of four from an assumed homogeneous isotropic tissue to an assumed anisotropic heterogenous tissue. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
19. A novel murine model of combined insulin-dependent diabetes and chronic kidney disease has greater skeletal detriments than either disease individually.
- Author
-
Damrath, John G., Metzger, Corinne E., Allen, Matthew R., and Wallace, Joseph M.
- Subjects
- *
TYPE 1 diabetes , *CHRONIC kidney failure , *HYPERGLYCEMIA , *BONE health , *BONE mechanics , *BLOOD urea nitrogen - Abstract
Diabetes and chronic kidney disease (CKD) consistently rank among the top ten conditions in prevalence and mortality in the United States. Insulin-dependent diabetes (IDD) and CKD each increase the risk of skeletal fractures and fracture-related mortality. However, it remains unknown whether these conditions have interactive end-organ effects on the skeleton. We hypothesized that combining IDD and CKD in mice would cause structural and mechanical bone alterations that are more deleterious compared to the single disease states. Female C57BL6/J mice were divided into four groups: 1) N = 12 Control (CTRL), 2) N = 10 Streptozotocin-induced IDD (STZ), 3) N = 10 Adenine diet-induced CKD (AD), and 4) N = 9 Combination (STZ+AD). STZ administration resulted in significantly higher blood glucose, HbA1c (p < 0.0001), and glucose intolerance (p < 0.0001). AD resulted in higher blood urea nitrogen (p = 0.0002) while AD, but not STZ+AD mice, had high serum parathyroid hormone (p < 0.0001) and phosphorus (p = 0.0005). STZ lowered bone turnover (p = 0.001). Trabecular bone volume was lowered by STZ (p < 0.0001) and increased by AD (p = 0.003). Tissue mineral density was lowered by STZ (p < 0.0001) and AD (p = 0.02) in trabecular bone but only lowered by STZ in cortical bone (p = 0.002). Cortical porosity of the proximal tibia was increased by AD, moment of inertia was lower in both disease groups, and most cortical properties were lower in all groups vs CTRL. Ultimate force, stiffness, toughness, and total displacement/strain were lowered by STZ and AD. Fracture toughness was lower by AD (p = 0.003). Importantly, Cohen's D indicated that STZ+AD most strongly lowered bone turnover and mechanical properties. Taken together, structural and material-level bone properties are altered by STZ and AD while their combination resulted in greater detriments, indicating that improving bone health in the combined disease state may require novel interventions. • IDD and CKD can be reliably induced together in C57BL/6 mice. • STZ and STZ+AD mice demonstrate persistent hyperglycemia and glucose intolerance. • AD, but not STZ+AD mice, show hyperparathyroidism and increased serum phosphorus. • STZ+AD mice have detriments in bone turnover, structural, and mechanical properties. • The magnitude of changes in skeletal properties were frequently greatest in STZ+AD. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
20. Combining raloxifene and mechanical loading improves bone composition and mechanical properties in a murine model of chronic kidney disease (CKD).
- Author
-
Surowiec, Rachel K., Reul, Olivia N., Chowdhury, Nusaiba N., Rai, Ratan K., Segvich, Dyann, Tomaschke, Andrew A., Damrath, John, Jacobson, Andrea M., Allen, Matthew R., and Wallace, Joseph M.
- Subjects
- *
BONE mechanics , *CHRONIC kidney failure , *RALOXIFENE , *TISSUE mechanics , *COMPACT bone , *SUBCUTANEOUS injections - Abstract
Patients with chronic kidney disease (CKD) are at an alarming risk of fracture compared to age and sex-matched non-CKD individuals. Clinical and preclinical data highlight two key factors in CKD-induced skeletal fragility: cortical porosity and reduced matrix-level properties including bone hydration. Thus, strategies are needed to address these concerns to improve mechanical properties and ultimately lower fracture risk in CKD. We sought to evaluate the singular and combined effects of mechanical and pharmacological interventions on modulating porosity, bone hydration, and mechanical properties in CKD. Sixteen-week-old male C57BL/6J mice underwent a 10-week CKD induction period via a 0.2 % adenine-laced casein-based diet (n = 48) or remained as non-CKD littermate controls (Con, n = 48). Following disease induction (26 weeks of age), n = 7 CKD and n = 7 Con were sacrificed (baseline cohort) to confirm a steady-state CKD state was achieved prior to the initiation of treatment. At 27 weeks of age, all remaining mice underwent right tibial loading to a maximum tensile strain of 2050 μƐ 3× a week for five weeks with the contralateral limb as a non-loaded control. Half of the mice (equal number CKD and Con) received subcutaneous injections of 0.5 mg/kg raloxifene (RAL) 5× a week, and the other half remained untreated (UN). Mice were sacrificed at 31 weeks of age. Serum biochemistries were performed, and bi-lateral tibiae were assessed for microarchitecture, whole bone and tissue level mechanical properties, and composition including bone hydration. Regardless of intervention, BUN and PTH were higher in CKD animals throughout the study. In CKD, the combined effects of loading and RAL were quantified as lower cortical porosity and improved mechanical, material, and compositional properties, including higher matrix-bound water. Loading was generally responsible for positive impacts in cortical geometry and structural mechanical properties, while RAL treatment improved some trabecular outcomes and material-level mechanical properties and was responsible for improvements in several compositional parameters. While control animals responded positively to loading, their bones were less impacted by the RAL treatment, showing no deformation, toughness, or bound water improvements which were all evident in CKD. Serum PTH levels were negatively correlated with matrix-bound water. An effective treatment program to improve fracture risk in CKD ideally focuses on the cortical bone and considers both cortical porosity and matrix properties. Loading-induced bone formation and mechanical improvements were observed across groups, and in the CKD cohort, this included lower cortical porosity. This study highlights that RAL treatment superimposed on active bone formation may be ideal for reducing skeletal complications in CKD by forming new bone with enhanced matrix properties. • Raloxifene-treated CKD animals had higher bound water. • Loading in CKD resulted in improved cortical outcomes and mechanical properties. • Loading plus raloxifene resulted in even tougher, more ductile, and stronger bones. • Control animals responded positively to loading but were less impacted by raloxifene. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Microcrack density and nanomechanical properties in the subchondral region of the immature piglet femoral head following ischemic osteonecrosis
- Author
-
Aruwajoye, Olumide O., Patel, Mihir K., Allen, Matthew R., Burr, David B., Aswath, Pranesh B., and Kim, Harry K.W.
- Subjects
- *
BONE density , *NANOMECHANICS , *BONE mechanics , *OSTEONECROSIS , *FEMUR , *ISCHEMIA , *LABORATORY swine - Abstract
Abstract: Development of a subchondral fracture is one of the earliest signs of structural failure of the immature femoral head following ischemic osteonecrosis, and this eventually leads to a flattening deformity of the femoral head. The mechanical and mineralization changes in the femoral head preceding subchondral fracture have not been elucidated. We hypothesized that ischemic osteonecrosis leads to early material and mechanical alterations in the bone of the subchondral region. The purpose of this investigation was to assess the bone of the subchondral region for changes in the histology of bone cells, microcrack density, mineral content, and nanoindentation properties at an early stage of ischemic osteonecrosis in a piglet model. This large animal model has been shown to develop a subchondral fracture and femoral head deformity resembling juvenile femoral head osteonecrosis. The unoperated, left femoral head of each piglet (n=8) was used as a normal control, while the right side had a surgical ischemia induced by disrupting the femoral neck vessels with a ligature. Hematoxylin and eosin (H&E) staining and TUNEL assay were performed on femoral heads from 3 piglets. Quantitative backscattered electron imaging, nanoindentation, and microcrack assessments were performed on the subchondral region of both control and ischemic femoral heads from 5 piglets. H&E staining and TUNEL assay showed extensive cell death and an absence of osteoblasts in the ischemic side compared to the normal control. Microcrack density in the ischemic side (3.2±0.79 cracks/mm2) was significantly higher compared to the normal side (0.27±0.27 cracks/mm2) in the subchondral region (p<0.05). The weighted mean of the weight percent distribution of calcium (CaMean) also was significantly higher in the ischemic subchondral region (p<0.05). Furthermore, the nanoindentation modulus within localized areas of subchondral bone was significantly increased in the ischemic side (16.8±2.7GPa) compared to the normal control (13.3±3.2GPa) (p<0.05). Taken together, these results support the hypothesis that the nanoindentation modulus of the subchondral trabecular bone is increased in the early stage of ischemic osteonecrosis of the immature femoral head and makes it more susceptible to microcrack formation. We postulate that continued loading of the hip joint when there is a lack of bone cells to repair the microcracks due to ischemic osteonecrosis leads to microcrack accumulation and subsequent subchondral fracture. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
22. Effects of novel raloxifene analogs alone or in combination with mechanical loading in the Col1a2G610c/+ murine model of osteogenesis imperfecta.
- Author
-
Kohler, Rachel, Creecy, Amy, Williams, David R., Allen, Matthew R., and Wallace, Joseph M.
- Subjects
- *
OSTEOGENESIS imperfecta , *RALOXIFENE , *BONE mechanics , *SELECTIVE estrogen receptor modulators , *BONE diseases - Abstract
Osteogenesis imperfecta (OI) is a hereditary bone disease in which gene mutations affect collagen formation, leading to a weak, brittle bone phenotype that can cause severe skeletal deformity and increased fracture risk. OI interventions typically repurpose osteoporosis medications to increase bone mass, but this approach does not address compromised tissue-level material properties. Raloxifene (RAL) is a mild anti-resorptive used to treat osteoporosis that has also been shown to increase bone strength by a-cellularly increasing bone bound water content, but RAL cannot be administered to children due to its hormonal activity. The goal of this study was to test a RAL analog with no estrogen receptor (ER) signaling but maintained ability to reduce fracture risk. The best performing analog from a previous analog characterization project, named RAL-ADM, was tested in an in vivo study. Female wildtype (WT) and Col1a2 G610C/+ (G610C) mice were randomly assigned to treated or untreated groups, for a total of 4 groups (n = 15). Starting at 10 weeks of age, all mice underwent compressive tibial loading 3×/week to induce an anabolic bone formation response in conjunction with RAL-ADM treatment (0.5 mg/kg; 5×/week) for 6 weeks. Tibiae were scanned via microcomputed tomography then tested to failure in four-point bending. RAL-ADM had reduced ER affinity, and increased post-yield properties, but did not improve bone strength in OI animals, suggesting some properties can be improved by RAL analogs but further development is needed to create an analog with decidedly positive impacts to OI bone. • Modulating tissue hydration may improve material properties of diseased bone. • Raloxifene enhances bone fracture resistance by acellularly increasing bound water. • A raloxifene analog could improve bone mechanics without estrogenic activity. • An analog was tested on a murine model of osteogenesis imperfecta. • The analog had some toughening effects but failed overall to improve bone mechanics. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
23. Zoledronate and Raloxifene combination therapy enhances material and mechanical properties of diseased mouse bone.
- Author
-
Powell, Katherine M., Skaggs, Cayla, Pulliam, Alexis, Berman, Alycia, Allen, Matthew R., and Wallace, Joseph M.
- Subjects
- *
COMPACT bone , *MECHANICAL behavior of materials , *RALOXIFENE , *BONE mechanics , *ZOLEDRONIC acid , *FRACTURE toughness - Abstract
Current interventions to reduce skeletal fragility are insufficient at enhancing both the quantity and quality of bone when attempting to improve overall mechanical integrity. Bisphosphonates, such as Zoledronate (ZOL), are used to treat a variety of bone disorders by increasing bone mass to decrease fracture risk, but long-term use has been shown in some settings to compromise bone quality. Alternatively, Raloxifene (RAL) has recently been demonstrated to improve tissue quality and overall mechanical properties in a cell-independent manner by binding to collagen and increasing tissue hydration. We hypothesized that a combination of RAL and ZOL would improve mechanical and material properties of bone more than either monotherapy alone by enhancing both quantity and quality. In this study, wildtype (WT) and heterozygous (OIM+/−) male mice from the Osteogenesis Imperfecta (OI) murine model were treated with either RAL, ZOL, or both from 8 weeks to 16 weeks of age. Using the OIM model allows for investigation of therapeutic effects on a quality-based bone disease. Combination treatment resulted in higher trabecular architecture, cortical mechanical properties, and cortical fracture toughness in diseased mouse bone. Two fracture toughness properties, which are direct measures of the tissue's ability to resist the initiation and propagation of a crack, were significantly improved with combination treatment in OIM+/− compared to control. There was no significant effect on fracture toughness with either monotherapy alone in either genotype. Following the mass-based effects of ZOL, trabecular bone volume fraction was significantly higher with combination treatment in both genotypes. Combination treatment resulted in higher ultimate stress in both genotypes. RAL and combination treatment in OIM+/− also increased resilience compared to the control. In conclusion, this study demonstrates the beneficial effects of using combination drug treatments to increase bone mass while simultaneously improving tissue quality, especially to enhance the mechanical integrity of diseased bone. Combination therapies could be a potential method to improve bone health and combat skeletal fragility on both the microscopic and macroscopic levels. • Combination treatment of Raloxifene and Zoledronate was investigated in the Osteogenesis Imperfect murine model. • Bone architecture, biomechanics, and fracture toughness were assessed in hindlimbs. • Combination treatment followed the quantity-based effects of Zoledronate with increases in trabecular microarchitecture. • Raloxifene drove the mechanical changes in the combination treatment. • Fracture toughness improved only with combination treatment in heterozygous diseased bone. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
24. Short-term pharmacologic RAGE inhibition differentially affects bone and skeletal muscle in middle-aged mice.
- Author
-
Davis, Hannah M., Essex, Alyson L., Valdez, Sinai, Deosthale, Padmini J., Aref, Mohammad W., Allen, Matthew R., Bonetto, Andrea, and Plotkin, Lilian I.
- Subjects
- *
RECEPTOR for advanced glycation end products (RAGE) , *ADVANCED glycation end-products , *SKELETAL muscle , *BONE mechanics , *LEAN body mass , *BODY composition - Abstract
Loss of bone and muscle mass are two major clinical complications among the growing list of chronic diseases that primarily affect elderly individuals. Persistent low-grade inflammation, one of the major drivers of aging, is also associated with both bone and muscle dysfunction in aging. Particularly, chronic activation of the receptor for advanced glycation end products (RAGE) and elevated levels of its ligands high mobility group box 1 (HMGB1), AGEs, S100 proteins and Aβ fibrils have been linked to bone and muscle loss in various pathologies. Further, genetic or pharmacologic RAGE inhibition has been shown to preserve both bone and muscle mass. However, whether short-term pharmacologic RAGE inhibition can prevent early bone and muscle loss in aging is unknown. To address this question, we treated young (4-mo) and middle-aged (15-mo) C57BL/6 female mice with vehicle or Azeliragon, a small-molecule RAGE inhibitor initially developed to treat Alzheimer's disease. Azeliragon did not prevent the aging-induced alterations in bone geometry or mechanics, likely due to its differential effects [direct vs. indirect] on bone cell viability/function. On the other hand, Azeliragon attenuated the aging-related body composition changes [fat and lean mass] and reversed the skeletal muscle alterations induced with aging. Interestingly, while Azeliragon induced similar metabolic changes in bone and skeletal muscle, aging differentially altered the expression of genes associated with glucose uptake/metabolism in these two tissues, highlighting a potential explanation for the differential effects of Azeliragon on bone and skeletal muscle in middle-aged mice. Overall, our findings suggest that while short-term pharmacologic RAGE inhibition did not protect against early aging-induced bone alterations, it prevented against the early effects of aging in skeletal muscle. • Short-term RAGE inhibition with Azeliragon (AZ) attenuated the aging-related body composition changes in fat and lean mass. • AZ administration reversed the skeletal muscle alterations induced in early aging. • AZ did not prevent the aging-induced bone alterations, likely due to its differential effects on bone cell viability/function. • Aging differentially altered glut transporter and metabolic enzyme expression in bone and skeletal muscle. • AZ treatment had differential effects on bone and skeletal muscle in middle-aged mice. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
25. Ex vivo exposure to calcitonin or raloxifene improves mechanical properties of diseased bone through non-cell mediated mechanisms.
- Author
-
Surowiec, Rachel K., Saldivar, Rosario, Rai, Ratan K., Metzger, Corinne E., Jacobson, Andrea M., Allen, Matthew R., and Wallace, Joseph M.
- Subjects
- *
RALOXIFENE , *BONE mechanics , *NUCLEAR magnetic resonance spectroscopy , *MAGIC angle spinning , *CALCITONIN , *CEREBRAL cortical thinning - Abstract
Raloxifene (RAL) reduces clinical fracture risk despite modest effects on bone mass and density. This reduction in fracture risk may be due to improved material level-mechanical properties through a non-cell mediated increase in bone hydration. Synthetic salmon calcitonin (CAL) has also demonstrated efficacy in reducing fracture risk with only modest bone mass and density improvements. This study aimed to determine if CAL could modify healthy and diseased bone through cell-independent mechanisms that alter hydration similar to RAL. 26-week-old male C57BL/6 mice induced with chronic kidney disease (CKD) beginning at 16 weeks of age via 0.2 % adenine-laced casein-based (0.9 % P, 0.6 % C) chow, and their non-CKD control littermates (Con), were utilized. Upon sacrifice, right femora were randomly assigned to the following ex vivo experimental groups: RAL (2 μM, n = 10 CKD, n = 10 Con), CAL (100 nM, n = 10 CKD, n = 10 Con), or Vehicle (VEH; n = 9 CKD, n = 9 Con). Bones were incubated in PBS + drug solution at 37 °C for 14 days using an established ex vivo soaking methodology. Cortical geometry (μCT) was used to confirm a CKD bone phenotype, including porosity and cortical thinning, at sacrifice. Femora were assessed for mechanical properties (3-point bending) and bone hydration (via solid state nuclear magnetic resonance spectroscopy with magic angle spinning (ssNMR)). Data were analyzed by two-tailed t -tests (μCT) or 2-way ANOVA for main effects of disease, treatment, and their interaction. Tukey's post hoc analyses followed a significant main effect of treatment to determine the source of the effect. Imaging confirmed a cortical phenotype reflective of CKD, including lower cortical thickness (p < 0.0001) and increased cortical porosity (p = 0.02) compared to Con. In addition, CKD resulted in weaker, less deformable bones. In CKD bones, ex vivo exposure to RAL or CAL improved total work (+120 % and +107 %, respectively; p < 0.05), post-yield work (+143 % and +133 %), total displacement (+197 % and +229 %), total strain (+225 % and +243 %), and toughness (+158 % and +119 %) vs. CKD VEH soaked bones. Ex vivo exposure to RAL or CAL did not impact any mechanical properties in Con bone. Matrix-bound water by ssNMR showed CAL treated bones had significantly higher bound water compared to VEH treated bones in both CKD and Con cohorts (p = 0.001 and p = 0.01, respectively). RAL positively modulated bound water in CKD bone compared to VEH (p = 0.002) but not in Con bone. There were no significant differences between bones soaked with CAL vs. RAL for any outcomes measured. RAL and CAL improve important post-yield properties and toughness in a non-cell mediated manner in CKD bone but not in Con bones. While RAL treated CKD bones had higher matrix-bound water content in line with previous reports, both Con and CKD bones exposed to CAL had higher matrix-bound water. Therapeutic modulation of water, specifically the bound water fraction, represents a novel approach to improving mechanical properties and potentially reducing fracture risk. • Therapeutic modulation of water represents a shift in current treatment paradigms. • Raloxifene or calcitonin elicits acellular improvements to material-level properties. • Bone exposed ex vivo to either compound had higher bound water concentrations. • Ex vivo exposure to either compound improved tissue toughness. • Bone from a chronic kidney disease model responded most robustly vs. control bone. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
26. Reference point indentation is insufficient for detecting alterations in traditional mechanical properties of bone under common experimental conditions.
- Author
-
Krege, John B., Aref, Mohammad W., McNerny, Erin, Wallace, Joseph M., Organ, Jason M., and Allen, Matthew R.
- Subjects
- *
INDENTATION (Materials science) , *BONE mechanics , *IN vivo studies , *BONE ash , *DEMINERALIZATION , *RALOXIFENE , *FRACTURE mechanics - Abstract
Reference point indentation (RPI) was developed as a novel method to assess mechanical properties of bone in vivo, yet it remains unclear what aspects of bone dictate changes/differences in RPI-based parameters. The main RPI parameter, indentation distance increase (IDI), has been proposed to be inversely related to the ability of bone to form/tolerate damage. The goal of this work was to explore the relationshipre-intervention RPI measurebetween RPI parameters and traditional mechanical properties under varying experimental conditions (drying and ashing bones to increase brittleness, demineralizing bones and soaking in raloxifene to decrease brittleness). Beams were machined from cadaveric bone, pre-tested with RPI, subjected to experimental manipulation, post-tested with RPI, and then subjected to four-point bending to failure. Drying and ashing significantly reduced RPI's IDI, as well as ultimate load (UL), and energy absorption measured from bending tests. Demineralization increased IDI with minimal change to bending properties. Ex vivo soaking in raloxifene had no effect on IDI but tended to enhance post-yield behavior at the structural level. These data challenge the paradigm of an inverse relationship between IDI and bone toughness, both through correlation analyses and in the individual experiments where divergent patterns of altered IDI and mechanical properties were noted. Based on these results, we conclude that RPI measurements alone, as compared to bending tests, are insufficient to reach conclusions regarding mechanical properties of bone. This proves problematic for the potential clinical use of RPI measurements in determining fracture risk for a single patient, as it is not currently clear that there is an IDI, or even a trend of IDI, that can determine clinically relevant changes in tissue properties that may contribute to whole bone fracture resistance. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
27. Raloxifene reduces skeletal fractures in an animal model of osteogenesis imperfecta.
- Author
-
Berman, Alycia G., Wallace, Joseph M., Bart, Zachary R., and Allen, Matthew R.
- Subjects
- *
RALOXIFENE , *OSTEOGENESIS imperfecta , *FRACTURE fixation , *BONE mechanics , *BONE density , *ANIMAL models in research , *THERAPEUTICS - Abstract
Osteogenesis imperfecta (OI) is a genetic disease of Type I collagen and collagen-associated pathways that results in brittle bone behavior characterized by fracture and reduced mechanical properties. Based on previous work in our laboratory showing that raloxifene (RAL) can significantly improve bone mechanical properties through non-cellular mechanisms, we hypothesized that raloxifene would improve the mechanical properties of OI bone. In experiment 1, tibiae from female wild type (WT) and homozygous oim mice were subjected to in vitro soaking in RAL followed by mechanical tests. RAL soaking resulted in significantly higher post-yield displacement (+ 75% in WT, + 472% in oim; p < 0.004), with no effect on ultimate load or stiffness, in both WT and oim animals. In experiment 2, eight-week old WT and oim male mice were treated for eight weeks with saline vehicle (VEH) or RAL. Endpoint measures included assessment of in vivo skeletal fractures, bone density/geometry and mechanical properties. In vivo skeletal fractures of the femora, assessed by micro CT imaging, were significantly lower in oim-RAL (20%) compared to oim-VEH (48%, p = 0.047). RAL led to significantly higher DXA-based BMD (p < 0.01) and CT-based trabecular BV/TV in both WT and oim animals compared to those treated with VEH. Fracture toughness of the femora was lower in oim mice compared to WT and improved with RAL in both genotypes. These results suggest that raloxifene reduces the incidence of fracture in this mouse model of oim. Furthermore, they suggest that raloxifene's effects may be the result of both cellular (increased bone mass) and non-cellular (presumably changes in hydration) mechanisms, raising the possibility of using raloxifene, or related compounds, as a new approach for treating bone fragility associated with OI. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
28. Cortical porosity development and progression is mitigated after etelcalcetide treatment in an animal model of chronic kidney disease.
- Author
-
Swallow, Elizabeth A., Metzger, Corinne E., Newman, Christopher L., Chen, Neal X., Moe, Sharon M., and Allen, Matthew R.
- Subjects
- *
CHRONIC kidney failure , *BONE mechanics , *SPRAGUE Dawley rats , *FRACTURE healing , *PEDIATRIC nephrology , *POROSITY , *RENAL osteodystrophy - Abstract
Chronic kidney disease (CKD) leads to increased bone fragility and risk of fracture. Cortical deteriorations, including cortical porosity, are key factors in fracture susceptibility in CKD. Since secondary hyperparathyroidism is common in CKD individuals and contributes to cortical deterioration, we hypothesized that reducing parathyroid hormone (PTH) may modulate CKD-induced cortical porosity. The goal of this pilot study was to assess the effects of lowering PTH, via the preclinical analogue of the FDA-approved calcimimetic etelcalcetide (KP-2326), on the development and progression of cortical pores in the setting of CKD. Male Cy/+ Sprague Dawley rats with clinical biochemistries consistent with CKD (N = 8) were assigned to the study. At 30–32 weeks of age, cortical bone was assessed via In vivo μCT and blood collected for biochemistries to create baseline measures. Calcimimetic treatment with KP-2326 (KP) was then administered 3× weekly for 2–4 weeks. Cortical bone and biochemical parameters were repeated at study endpoint (33–37 wks of age). A group of age- and cohort-matched CKD rats (N = 4) were utilized as untreated controls. Untreated CKD rats had significantly increased cortical porosity over time, while porosity in KP-treated CKD rats was not significantly changed over time. Individual pore analysis revealed that pore area was significantly higher for expanding pores in untreated CKD rats compared to KP-treated CKD rats. Mechanical properties of KP-treated animal femora were similar to historical values of age-matched CKD animals and lower than those of age-matched non-diseased animals. Our pilot preclinical study demonstrates that etelcalcetide treatment can mitigate the progression of cortical bone changes in an animal model of CKD through suppression of pre-existing cortical pore expansion and limiting the size of new pore development. While stabilization of porosity is beneficial it remains likely that infilling of porosity will be needed to positively affect mechanical properties of bones in the setting of CKD. • The preclinical analogue of etelcalcetide was used in rats with progressive CKD. • Treatment stabilized cortical porosity by limiting pore expansion and development. • Individual cortical pore tracking over time documents dynamic activity in CKD animals. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
29. In vivo reference point indentation reveals positive effects of raloxifene on mechanical properties following 6months of treatment in skeletally mature beagle dogs.
- Author
-
Aref, Mohammad, Gallant, Maxime A., Organ, Jason M., Wallace, Joseph M., Newman, Christopher L., Burr, David B., Brown, Drew M., and Allen, Matthew R.
- Subjects
- *
RALOXIFENE , *BONE mechanics , *TIBIAL nerve , *TREATMENT duration , *LABORATORY dogs , *ORAL drug administration , *DRUG dosage , *THERAPEUTICS - Abstract
Abstract: Raloxifene treatment has been shown previously to positively affect bone mechanical properties following 1year of treatment in skeletally mature dogs. Reference point indentation (RPI) can be used for in vivo assessment of mechanical properties and has been shown to produce values that are highly correlated with properties derived from traditional mechanical testing. The goal of this study was to use RPI to determine if raloxifene-induced alterations in mechanical properties occurred after 6months of treatment. Twelve skeletally mature female beagle dogs were treated for 6months with oral doses of saline vehicle (VEH, 1ml/kg/day) or a clinically relevant dose of raloxifene (RAL, 0.5mg/kg/day). At 6months, all animals underwent in vivo RPI (10N force, 10cycles) of the anterior tibial midshaft. RPI data were analyzed using a custom MATLAB program, designed to provide cycle-by-cycle data from the RPI test and validated against the manufacturer-provided software. Indentation distance increase (IDI), a parameter that is inversely related to bone toughness, was significantly lower in RAL-treated animals compared to VEH (−16.5%), suggesting increased bone toughness. Energy absorption within the first cycle was significantly lower with RAL compared to VEH (−21%). These data build on previous work that has documented positive effects of raloxifene on material properties by showing that these changes exist after 6months. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
30. The combination of aging and chronic kidney disease leads to an exacerbated cortical porosity phenotype.
- Author
-
Tippen, Samantha P., Metzger, Corinne E., Swallow, Elizabeth A., Sacks, Spencer A., Wallace, Joseph M., and Allen, Matthew R.
- Subjects
- *
CHRONIC kidney failure , *AGING , *PHENOTYPES , *MECHANICAL behavior of materials , *BONE mechanics - Abstract
Chronic kidney disease (CKD) and aging are each independently associated with higher fracture risk. Although CKD is highly prevalent in the aging population, the interaction between these two conditions with respect to bone structure and mechanics is not well understood. The purpose of this study was to examine cortical porosity and mechanical properties in skeletally mature young and aging mice with CKD. CKD was induced by feeding 16-week and 78-week male mice 0.2% adenine (AD) for six weeks followed by two weeks of maintenance on a control diet for a total study duration of eight weeks of CKD; control (CON) animals of each age were fed a standard diet. Serum biochemistries, μCT imaging, and mechanical properties via four-point bending were assessed at the endpoint. Phosphorus, parathyroid hormone, and blood urea nitrogen were elevated in both ages of AD mice compared to age-matched CON; aging AD mice had PTH and BUN values higher than all other groups. Femoral cortical porosity was more than four-fold higher in aging AD mice compared to young AD mice and more than two-fold higher compared to age-matched controls. Structural and estimated material mechanical properties were both lower in aging mice, but there were no significant interactions between AD treatment and age. These data show an interaction between CKD and aging that produces a more severe biochemical and cortical bone phenotype. This highlights the importance of studying mechanisms and potential interventions in both young and aged animals to translate to a broader spectrum of CKD patients. • Adenine-induced CKD causes high PTH and cortical porosity in young and aging mice. • Aging adenine mice had greater PTH and cortical porosity than young adenine mice. • Adenine and aging both independently impacted bone mechanics. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
31. Reference-point indentation correlates with bone toughness assessed using whole-bone traditional mechanical testing
- Author
-
Gallant, Maxime A., Brown, Drew M., Organ, Jason M., Allen, Matthew R., and Burr, David B.
- Subjects
- *
BONE mechanics , *FRACTURE toughness , *DIPHOSPHONATES , *TREATMENT of diabetes , *COMPRESSION fractures , *ANIMAL models in research , *INDENTATION (Materials science) - Abstract
Abstract: Traditional bone mechanical testing techniques require excised bone and destructive sample preparation. Recently, a cyclic-microindentation technique, reference-point indentation (RPI), was described that allows bone to be tested in a clinical setting, permitting the analysis of changes to bone material properties over time. Because this is a new technique, it has not been clear how the measurements generated by RPI are related to the material properties of bone measured by standard techniques. In this paper, we describe our experience with the RPI technique, and correlate the results obtained by RPI with those of traditional mechanical testing, namely 3-point bending and axial compression. Using different animal models, we report that apparent bone material toughness obtained from 3-point bending and axial compression is inversely correlated with the indentation distance increase (IDI) obtained from RPI with r 2 values ranging from 0.50 to 0.57. We also show that conditions or treatments previously shown to cause differences in toughness, including diabetes and bisphosphonate treatment, had significantly different IDI values compared to controls. Collectively these results provide a starting point for understanding how RPI relates to traditional mechanical testing results. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
32. Sost downregulation and local Wnt signaling are required for the osteogenic response to mechanical loading
- Author
-
Tu, Xiaolin, Rhee, Yumie, Condon, Keith W., Bivi, Nicoletta, Allen, Matthew R., Dwyer, Denise, Stolina, Marina, Turner, Charles H., Robling, Alexander G., Plotkin, Lilian I., and Bellido, Teresita
- Subjects
- *
BONE growth , *BONE mechanics , *CELLULAR signal transduction , *GENETIC regulation , *GLYCOPROTEINS , *OSTEOCYTES , *OSTEOBLASTS - Abstract
Abstract: Sclerostin, the Wnt signaling antagonist encoded by the Sost gene, is secreted by osteocytes and inhibits bone formation by osteoblasts. Mechanical stimulation reduces sclerostin expression, suggesting that osteocytes might coordinate the osteogenic response to mechanical force by locally unleashing Wnt signaling. To investigate whether sclerostin downregulation is a pre-requisite for load-induced bone formation, we conducted experiments in transgenic mice (TG) engineered to maintain high levels of SOST expression during mechanical loading. This was accomplished by introducing a human SOST transgene driven by the 8kb fragment of the DMP1 promoter that also provided osteocyte specificity of the transgene. Right ulnae were subjected to in vivo cyclic axial loading at equivalent strains for 1min/day at 2Hz; left ulnae served as internal controls. Endogenous murine Sost mRNA expression measured 24h after 1 loading bout was decreased by about 50% in TG and wild type (WT) littermates. In contrast, human SOST, only expressed in TG mice, remained high after loading. Mice were loaded on 3 consecutive days and bone formation was quantified 16days after initiation of loading. Periosteal bone formation in control ulnae was similar in WT and TG mice. Loading induced the expected strain-dependent increase in bone formation in WT mice, resulting from increases in both mineralizing surface (MS/BS) and mineral apposition rate (MAR). In contrast, load-induced bone formation was reduced by 70–85% in TG mice, due to lower MS/BS and complete inhibition of MAR. Moreover, Wnt target gene expression induced by loading in WT mice was absent in TG mice. Thus, downregulation of Sost/sclerostin in osteocytes is an obligatory step in the mechanotransduction cascade that activates Wnt signaling and directs osteogenesis to where bone is structurally needed. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
33. Bisphosphonates do not inhibit periosteal bone formation in estrogen deficient animals and allow enhanced bone modeling in response to mechanical loading
- Author
-
Feher, Anthony, Koivunemi, Andrew, Koivunemi, Mark, Fuchs, Robyn K., Burr, David B., Phipps, Roger J., Reinwald, Susan, and Allen, Matthew R.
- Subjects
- *
DIPHOSPHONATES , *PERIOSTEUM , *ESTROGEN , *BONE mechanics , *BONE remodeling , *OVARIECTOMY , *OSTEOPOROSIS in women , *LABORATORY rats , *THERAPEUTICS - Abstract
Abstract: The suppressive effects of bisphosphonates (BPs) on bone remodeling are clear yet there is conflicting data concerning the effects of BPs on modeling (specifically formation modeling on the periosteal surface). The normal periosteal expansion that occurs during aging has significant benefits to maintaining/improving the bones'' mechanical properties and thus it is important to understand whether BPs affect this bone surface. Therefore, the purpose of this study was to determine the effects of BPs on periosteal bone formation modeling induced by ovariectomy (OVX) and mechanical loading. Six-month-old Sprague–Dawley OVX rats (n = 60; 12/group) were administered vehicle, risedronate, alendronate, or zoledronate at doses used clinically for treatment of post-menopausal osteoporosis. Three weeks after initiating BP treatment, all animals underwent in vivo ulnar loading of the right limb every other day for 1 week (3 total sessions). Periosteal surface mineral apposition rate, mineralizing surface, and bone formation rate were determined at the mid-diaphysis of both loaded (right) and non-loaded (left) ulnae. There was no significant effect of any of the BPs on periosteal bone formation parameters compared to VEH-treated animals in the non-loaded limb, suggesting that BP treatment does not compromise the normal periosteal expansion associated with estrogen loss. Mechanical loading significantly increased BFR in the loaded limb compared to the non-loaded limb in all BP-treated groups, with no difference in the magnitude of this effect among the various BPs. Collectively, these data show that BP treatment, at doses comparable to those used for treatment of post-menopausal osteoporosis, (1) does not alter the periosteal formation activity that occurs in the absence of estrogen and (2) allows normal stimulation of periosteal bone formation in response to the anabolic stimulation of mechanical loading. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
34. Reversing cortical porosity: Cortical pore infilling in preclinical models of chronic kidney disease.
- Author
-
Metzger, Corinne E., Swallow, Elizabeth A., Stacy, Alexander J., Tippen, Samantha P., Hammond, Max A., Chen, Neal X., Moe, Sharon M., and Allen, Matthew R.
- Subjects
- *
CHRONIC kidney failure , *ANIMAL models in research , *POROSITY , *BONE mechanics , *BLOOD urea nitrogen - Abstract
Chronic kidney disease (CKD) patients have a high incidence of fracture due in part to cortical porosity. The goal of this study was to study cortical pore infilling utilizing two rodent models of progressive CKD. Exp 1: Female C57Bl/6J mice (16-week-old) were given dietary adenine (0.2%) to induce CKD for 10 weeks after which calcium water supplementation (Ca-H 2 O; 1.5% and 3%) was given to suppress PTH for another 4 weeks. Exp 2: Male Cy/+ rats were aged to ~30 weeks with baseline porosity assessed using in vivo μCT. A second in vivo scan followed 5-weeks of Ca-H 2 O (3%) supplementation. Exp 1: Untreated adenine mice had elevated blood urea nitrogen (BUN), parathyroid hormone (PTH), and cortical porosity (~2.6% porosity) while Ca-H 2 O lowered PTH and cortical porosity (0.5–0.8% porosity). Exp 2: Male Cy/+ rats at baseline had variable porosity (0.5%–10%), but after PTH suppression via Ca-H 2 O, cortical porosity in all rats was lower than 0.5%. Individual pore dynamics measured via a custom MATLAB code demonstrated that 85% of pores infilled while 12% contracted in size. Ca-H 2 O supplementation causes net cortical pore infilling over time and imparted mechanical benefits. While calcium supplementation is not a viable clinical treatment for CKD, these data demonstrate pore infilling is possible and further research is required to examine clinically relevant therapeutics that may cause net pore infilling in CKD. • CKD-induced cortical porosity was reduced in rodent models after PTH suppression. • Reducing cortical porosity improves bone mechanics in mice with CKD. • Individual pore tracking over time documents pore infilling in CKD animals. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.